Company’s 36-month beta value is 1.94.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMNM is 76.80M, and currently, short sellers hold a 17.77% ratio of that floaft. The average trading volume of IMNM on May 23, 2025 was 1.13M shares.
IMNM) stock’s latest price update
Immunome Inc (NASDAQ: IMNM)’s stock price has increased by 6.82 compared to its previous closing price of 7.92. However, the company has seen a 5.75% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-05-22 that BOTHELL, Wash.–(BUSINESS WIRE)–Immunome to Present at Upcoming Investor Conferences.
IMNM’s Market Performance
Immunome Inc (IMNM) has experienced a 5.75% rise in stock performance for the past week, with a -0.47% drop in the past month, and a -11.13% drop in the past quarter. The volatility ratio for the week is 6.89%, and the volatility levels for the past 30 days are at 4.41% for IMNM. The simple moving average for the last 20 days is 3.44% for IMNM stock, with a simple moving average of -22.95% for the last 200 days.
Analysts’ Opinion of IMNM
Many brokerage firms have already submitted their reports for IMNM stocks, with Lake Street repeating the rating for IMNM by listing it as a “Buy.” The predicted price for IMNM in the upcoming period, according to Lake Street is $23 based on the research report published on April 02, 2025 of the current year 2025.
Stephens, on the other hand, stated in their research note that they expect to see IMNM reach a price target of $30. The rating they have provided for IMNM stocks is “Overweight” according to the report published on November 08th, 2024.
Piper Sandler gave a rating of “Overweight” to IMNM, setting the target price at $27 in the report published on May 31st of the previous year.
IMNM Trading at 9.47% from the 50-Day Moving Average
After a stumble in the market that brought IMNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.67% of loss for the given period.
Volatility was left at 4.41%, however, over the last 30 days, the volatility rate increased by 6.89%, as shares sank -0.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.14% lower at present.
During the last 5 trading sessions, IMNM rose by +5.75%, which changed the moving average for the period of 200-days by -31.53% in comparison to the 20-day moving average, which settled at $8.18. In addition, Immunome Inc saw -20.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNM starting from BIENAIME JEAN JACQUES, who purchase 7,800 shares at the price of $7.78 back on Mar 25 ’25. After this action, BIENAIME JEAN JACQUES now owns 31,415 shares of Immunome Inc, valued at $60,684 using the latest closing price.
SIEGALL CLAY B, the President and CEO of Immunome Inc, purchase 137,100 shares at $7.29 during a trade that took place back on Mar 26 ’25, which means that SIEGALL CLAY B is holding 806,736 shares at $999,459 based on the most recent closing price.
Stock Fundamentals for IMNM
Current profitability levels for the company are sitting at:
- -19.94 for the present operating margin
- 0.62 for the gross margin
The net margin for Immunome Inc stands at -18.75. The total capital return value is set at -0.7. Equity return is now at value -69.21, with -61.93 for asset returns.
Based on Immunome Inc (IMNM), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -32.01.
Currently, EBITDA for the company is -151.35 million with net debt to EBITDA at 1.42. When we switch over and look at the enterprise to sales, we see a ratio of 44.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.49.
Conclusion
In a nutshell, Immunome Inc (IMNM) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
